TY - JOUR
T1 - The wide utility of rabbits as models of human diseases
AU - Esteves, Pedro J.
AU - Abrantes, Joana
AU - Baldauf, Hanna Mari
AU - BenMohamed, Lbachir
AU - Chen, Yuxing
AU - Christensen, Neil
AU - González-Gallego, Javier
AU - Giacani, Lorenzo
AU - Hu, Jiafen
AU - Kaplan, Gilla
AU - Keppler, Oliver T.
AU - Knight, Katherine L.
AU - Kong, Xiang Peng
AU - Lanning, Dennis K.
AU - Le Pendu, Jacques
AU - De Matos, Ana Lemos
AU - Liu, Jia
AU - Liu, Shuying
AU - Lopes, Ana M.
AU - Lu, Shan
AU - Lukehart, Sheila
AU - Manabe, Yukari C.
AU - Neves, Fabiana
AU - McFadden, Grant
AU - Pan, Ruimin
AU - Peng, Xuwen
AU - de Sousa-Pereira, Patricia
AU - Pinheiro, Ana
AU - Rahman, Masmudur
AU - Ruvoën-Clouet, Natalie
AU - Subbian, Selvakumar
AU - Tuñón, Maria Jesús
AU - van der Loo, Wessel
AU - Vaine, Michael
AU - Via, Laura E.
AU - Wang, Shixia
AU - Mage, Rose
N1 - Funding Information:
This research was supported in part by the Intramural Research Program of the NIH, NIAID (R.M. and L.E.V.), in part by Bill and Melinda Gates Foundation grants OPP1034408 and OPP1140482 and in part by NIH grants AI082274 (S.L.), AI100151 (X.-P.K.), AI50260 and AI068390 (K.L.K. and D.L.), and R03AI119619 (S. S.). J.L. is supported in part by K22-A99184, P20GM103625, the Cookie Laughlin Award from the Rivkin Center for Ovarian Cancer, and a start-up fund by the UAMS Department of Microbiology and Immunology. L.B. is supported by the Public Health Service Research R01 Grant EY019896 and by the National Eye Institute (NEI). N.D.C. and J.H. are supported by NIH grant 5R01 CA47622 by the National Cancer Institute. H.-M.B. is supported by LMU Munich’s Institutional Strategy LMU excellent within the framework of the German Excellence Initiative. CIBERehd (J.G.-g and M.J.T.) is funded by the Instituto de Salud Carlos III, Spain. The Portuguese Foundation for Science and Technology (FCT) supported the FCT Investigator grants of J.A. (ref.: IF/01396/2013) and P.J.E. (ref.: IF/00376/2015), the Post-Doc grants of A.M.L. (ref.: SFRH/BPD/115211/2016) and A.P. (ref.: SFRH/BPD/117451/2016) and the PhD grants of P.d.S.P. (ref.: PD/ BD/52602/2014) and F.N. (SFRH/BD/81916/2011). J.L.P. is funded by Inserm.
Funding Information:
This research was supported in part by the Intramural Research Program of the NIH, NIAID (R.M. and L.E.V.), in part by Bill and Melinda Gates Foundation grants OPP1034408 and OPP1140482 and in part by NIH grants AI082274 (S.L.), AI100151 (X.-P.K.), AI50260 and AI068390 (K.L.K. and D.L.), and R03AI119619 (S. S.). J.L. is supported in part by K22-A99184, P20GM103625, the Cookie Laughlin Award from the Rivkin Center for Ovarian Cancer, and a start-up fund by the UAMS Department of Microbiology and Immunology. L.B. is supported by the Public Health Service Research R01 Grant EY019896 and by the National Eye Institute (NEI). N.D.C. and J.H. are supported by NIH grant 5R01 CA47622 by the National Cancer Institute. H.-M.B. is supported by LMU Munich’s Institutional Strategy LMU excellent within the framework of the German Excellence Initiative. CIBERehd (J.G.-g and M.J.T.) is funded by the Instituto de Salud Carlos III, Spain. The Portuguese Foundation for Science and Technology (FCT) supported the FCT Investigator grants of J.A. (ref.: IF/01396/2013) and P.J.E. (ref.: IF/00376/2015), the Post-Doc grants of A.M.L. (ref.: SFRH/BPD/115211/2016) and A.P. (ref.: SFRH/BPD/117451/2016) and the PhD grants of P.d.S.P. (ref.: PD/BD/52602/2014) and F.N. (SFRH/BD/81916/2011). J.L.P. is funded by Inserm.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/5
Y1 - 2018/5
N2 - Studies using the European rabbit Oryctolagus cuniculus contributed to elucidating numerous fundamental aspects of antibody structure and diversification mechanisms and continue to be valuable for the development and testing of therapeutic humanized polyclonal and monoclonal antibodies. Additionally, during the last two decades, the use of the European rabbit as an animal model has been increasingly extended to many human diseases. This review documents the continuing wide utility of the rabbit as a reliable disease model for development of therapeutics and vaccines and studies of the cellular and molecular mechanisms underlying many human diseases. Examples include syphilis, tuberculosis, HIV-AIDS, acute hepatic failure and diseases caused by noroviruses, ocular herpes, and papillomaviruses. The use of rabbits for vaccine development studies, which began with Louis Pasteur’s rabies vaccine in 1881, continues today with targets that include the potentially blinding HSV-1 virus infection and HIV-AIDS. Additionally, two highly fatal viral diseases, rabbit hemorrhagic disease and myxomatosis, affect the European rabbit and provide unique models to understand co-evolution between a vertebrate host and viral pathogens.
AB - Studies using the European rabbit Oryctolagus cuniculus contributed to elucidating numerous fundamental aspects of antibody structure and diversification mechanisms and continue to be valuable for the development and testing of therapeutic humanized polyclonal and monoclonal antibodies. Additionally, during the last two decades, the use of the European rabbit as an animal model has been increasingly extended to many human diseases. This review documents the continuing wide utility of the rabbit as a reliable disease model for development of therapeutics and vaccines and studies of the cellular and molecular mechanisms underlying many human diseases. Examples include syphilis, tuberculosis, HIV-AIDS, acute hepatic failure and diseases caused by noroviruses, ocular herpes, and papillomaviruses. The use of rabbits for vaccine development studies, which began with Louis Pasteur’s rabies vaccine in 1881, continues today with targets that include the potentially blinding HSV-1 virus infection and HIV-AIDS. Additionally, two highly fatal viral diseases, rabbit hemorrhagic disease and myxomatosis, affect the European rabbit and provide unique models to understand co-evolution between a vertebrate host and viral pathogens.
UR - http://www.scopus.com/inward/record.url?scp=85050810136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050810136&partnerID=8YFLogxK
U2 - 10.1038/s12276-018-0094-1
DO - 10.1038/s12276-018-0094-1
M3 - Article
C2 - 29789565
AN - SCOPUS:85050810136
SN - 1226-3613
VL - 50
JO - Experimental and Molecular Medicine
JF - Experimental and Molecular Medicine
IS - 5
M1 - 66
ER -